SOURCE: AtCor Medical Holdings Ltd.

AtCor Medical Holdings Ltd.

March 15, 2011 11:35 ET

AtCor Medical Announces New $0.6 Million Pharmaceutical Clinical Trials Contract

Noninvasive Central Blood Pressure Assessment Vital in Understanding Drug Effects

ITASCA, IL--(Marketwire - March 15, 2011) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new $0.6 million agreement to supply SphygmoCor systems and clinical trial support services in a new drug trial conducted by a major international pharmaceutical company.

Detecting potentially beneficial and detrimental effects on central pressures

Duncan Ross, CEO of AtCor Medical, said, "Over the past five years, there has been mounting evidence of potentially beneficial and detrimental drug effects on central blood pressures and arterial stiffness.* We are especially pleased that, as exemplified in this clinical trial, noninvasive central pressure assessment has grown beyond hypertension medications to encompass studies of drug effects of new and existing drug therapies in many drug classes. Noninvasive measurement of central blood pressures and arterial stiffness allows pharmaceutical companies and clinicians to more fully understand drug benefits and potential risks." 

"The growing recognition of the importance of central blood pressure assessment has been an important contributor to AtCor Medical's growth," Ross continued. "In the past 12 months, we have signed contracts for 9 new clinical trials and 4 study extensions. Our clients include leading international pharmaceutical companies and entrepreneurial drug and device companies. We are especially proud of our customers' response to the quality of the training, investigator site support, and information management technology we have incorporated as integral elements of our clinical trials offering. We truly offer a turnkey solution for the assessment of central pressures and arterial stiffness in clinical trials, working with trial sponsors and CROs, not as a supplier but as a trusted member of the team. 

About AtCor Medical

AtCor Medical's SphygmoCor systems are the gold standard for noninvasive assessment of central blood pressure and arterial stiffness, used globally in every stage of clinical trials and in clinical practice, featured in over 600 published studies. 

With SphygmoCor systems, the central blood pressure waveform, determined noninvasively from the radial artery waveform, provides critical reflected pressure data, used in assessing drug effects in trials, and in drug selection and therapy management by clinicians. AtCor provides comprehensive clinical trial support: SphygmoCor systems with PWA, PWV and HRV capabilities, trial site training, data quality assurance and data management using the AtCor WISDOM system.

More than 2,100 SphygmoCor systems are currently in use worldwide in major medical centers, research institutions, physicians' offices and in pharmaceutical clinical trials. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at

*Camafort-Babkowski Choosing an Antihypertensive Combination with a More Efficient Central Blood Pressure Reduction Expert Rev Cardiovascular Ther 2010; 8 (11):1523-1525

Contact Information

  • For further information, please contact:
    Duncan Ross
    AtCor Medical CEO
    (630) 228-8873

    Larry Watts
    AtCor Director, Marketing Services